In conclusion, the balanced activation of the three PPAR subtypes by MHY2013 improved obesity-induced insulin resistance, hepatic steatosis, and dyslipidemia without weight gain and severe toxicity. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.